Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits
暂无分享,去创建一个
Sebastian Schneckener | Thomas G Preuss | Donato Teutonico | Panteleimon D Mavroudis | T. Preuss | S. Schneckener | P. D. Mavroudis | D. Teutonico | H. E. Hermes | Helen E Hermes
[1] J. G. Hengstler,et al. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH) , 2008, Archives of Toxicology.
[2] Malcolm Rowland,et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.
[3] Thomas Hartung,et al. The dawning of a new age of toxicology. , 2008, ALTEX.
[4] Anna M. Wu,et al. A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.
[5] William J Jusko,et al. Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.
[6] Jingjing Yu,et al. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification , 2015, Drug Metabolism and Disposition.
[7] Walter Schmitt,et al. A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.
[8] Walter Schmitt,et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development , 2008 .
[9] M. Bonati,et al. Pharmacokinetics of theophylline and its metabolites in rabbits , 1985, European Journal of Drug Metabolism and Pharmacokinetics.
[10] Mirjam N Trame,et al. Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network , 2016, CPT: pharmacometrics & systems pharmacology.
[11] Melvin E Andersen,et al. Toxicokinetic modeling and its applications in chemical risk assessment. , 2003, Toxicology letters.
[12] W. Russell,et al. Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.
[13] Harvey J Clewell,et al. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.
[14] M. Block. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps , 2015, Expert opinion on drug metabolism & toxicology.
[15] M. Fujii,et al. Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. , 2001, Chemical & pharmaceutical bulletin.
[16] Walter Schmitt,et al. Physiology-based pharmacokinetic modeling: ready to be used. , 2004, Drug discovery today. Technologies.
[17] T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.
[18] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[19] A. Wolc,et al. Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan , 2012, Pharmacological reports : PR.
[20] J. Dressman,et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. , 2011, Journal of pharmaceutical sciences.
[21] Ioannis P. Androulakis,et al. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine , 2016, Journal of Pharmacokinetics and Pharmacodynamics.
[22] A. El‐Yazigi,et al. Theophylline absorption and disposition in rabbits: oral, intravenous, and concentration-dependent kinetic studies. , 1981, Journal of pharmaceutical sciences.
[23] D. Mager,et al. Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice , 2015, Journal of Pharmacokinetics and Pharmacodynamics.
[24] Walter Schmitt,et al. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .
[25] W. Nimmo,et al. Novel drug delivery and its therapeutic application , 1989 .
[26] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[27] I. Rietjens,et al. Prediction of in vivo developmental toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic modeling , 2014, Archives of Toxicology.
[28] J A Wiltse,et al. U.S. Environmental Protection Agency's revised guidelines for carcinogen risk assessment: evaluating a postulated mode of carcinogenic action in guiding dose-response extrapolation. , 2000, Mutation research.
[29] Walter Schmitt,et al. Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[30] George Loizou,et al. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.
[31] T. Terasaki,et al. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[32] M. Klepser,et al. Disposition of ofloxacin in female New Zealand white rabbits. , 1997, Journal of veterinary pharmacology and therapeutics.
[33] N. Yamagishi,et al. Using a single blood sample and inulin to estimate glomerular filtration rate in rabbits. , 2011, Journal of the American Association for Laboratory Animal Science : JAALAS.
[34] Hugh A Barton,et al. Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment. , 2013, Regulatory toxicology and pharmacology : RTP.
[35] U. Hofmann,et al. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. , 2015, Journal of pharmaceutical sciences.
[36] The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide , 2014, European Journal of Drug Metabolism and Pharmacokinetics.
[37] Xiaomei Zhuang,et al. PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.
[38] N Parrott,et al. Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.
[39] N. Heinrich,et al. Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence , 2015, ChemMedChem.
[40] Wolfgang Weiss,et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..
[41] H. Rochambeau,et al. The rabbit. Husbandry, health and production. , 1986 .
[42] Bienert Agnieszka,et al. Pharmacokinetics and ocular disposition of paracetamol and paracetamol glucuronide in rabbits with diabetes mellitus induced by alloxan , 2012 .
[43] Ioannis P. Androulakis,et al. Quantitative Systems Pharmacology: A Framework for Context , 2016, Current Pharmacology Reports.
[44] F. Theil,et al. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.
[45] B. Blount,et al. Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment , 2012, Journal of toxicology.
[46] E. M. Renkin,et al. Coupling of albumin flux to volume flow in skin and muscles of anesthetized rats. , 1988, The American journal of physiology.
[47] A. Walubo,et al. Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. , 2007, Basic & clinical pharmacology & toxicology.
[48] DE Mager,et al. Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.
[49] Lukas Furst,et al. Physiologically Based Pharmacokinetic Modeling Science And Applications , 2016 .
[50] A. Edginton,et al. Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development , 2014, CPT: pharmacometrics & systems pharmacology.
[51] Kannan Krishnan,et al. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.
[52] Jörg Lippert,et al. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.
[53] Hilda Witters,et al. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. , 2013, Regulatory toxicology and pharmacology : RTP.
[54] W. Schmitt,et al. A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.
[55] Thomas Hartung,et al. Food for thought... on animal tests. , 2008, ALTEX.
[56] E. Lim,et al. The National Kidney Foundation Guideline on Estimation of the Glomerular Filtration Rate , 2003 .
[57] N. Yamagishi,et al. Estimation of glomerular filtration rate in rabbits by a single-sample method using iodixanol , 2012, Laboratory animals.
[58] L. A. Fenu,et al. Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.
[59] Hugh A Barton,et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.
[60] Walter Schmitt,et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. , 2008, Expert opinion on drug metabolism & toxicology.